

<b>NCT ID</b>	NCT05198934
<b>Title</b>	Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2022-01-20
<b>Location</b>	Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Mexico South Korea Spain Taiwan United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

---

<b>NCT ID</b>	NCT05194735
<b>Title</b>	Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2022-01-18
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Terminated
<b>Drugs</b>	Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product
<b>Tags</b>	MSS/ MMRp

---

<b>NCT ID</b>	NCT05167409
<b>Title</b>	A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-12-22
<b>Location</b>	Arizona, United States Colorado, United States New Jersey, United States Virginia, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda

<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05141721
<b>Title</b>	A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-12-02
<b>Location</b>	Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05141474
<b>Title</b>	Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
<b>Phase</b>	Early Phase 1
<b>Date Added</b>	2021-12-02
<b>Location</b>	Spain
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05107674
<b>Title</b>	A Study of NX-1607 in Adults With Advanced Malignancies
<b>Phase</b>	Phase 1
<b>Date Added</b>	2021-11-04

<b>Location</b>	California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	NX-1607
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05019534
<b>Title</b>	Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2021-08-25
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Camrelizumab, Cetuximab Injection [Erbix], Vemurafenib Oral Tablet [Zelboraf]
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04991948
<b>Title</b>	Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2021-08-05
<b>Location</b>	Florida, United States Belgium
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	CYAD-101, FOLFOX, Pembrolizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04984369
<b>Title</b>	The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-07-30
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Cetuximab Injection [Erbix], HLX208
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04973163
<b>Title</b>	A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Phase	Phase 1
Date Added	2021-07-22
Location	Texas, United States Belgium Spain United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	BI 1701963, BI 1823911, Midazolam
Tags	MSS/ MMRp